Your browser doesn't support javascript.
loading
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Oo, Zay Yar; Proctor, Martina; Stevenson, Alexander J; Nazareth, Deborah; Fernando, Madushan; Daignault, Sheena M; Lanagan, Catherine; Walpole, Sebastian; Bonazzi, Vanessa; Skalamera, Dubravka; Snell, Cameron; Haass, Nikolas K; Larsen, Jill E; Gabrielli, Brian.
Afiliação
  • Oo ZY; Smiling for Smiddy Research Group, Translational Research Institute, Mater Research Institute-The University of Queensland, Brisbane, Australia.
  • Proctor M; Translational Research Institute, The University of Queensland-Diamantina Institute, Brisbane, Australia.
  • Stevenson AJ; Smiling for Smiddy Research Group, Translational Research Institute, Mater Research Institute-The University of Queensland, Brisbane, Australia.
  • Nazareth D; Smiling for Smiddy Research Group, Translational Research Institute, Mater Research Institute-The University of Queensland, Brisbane, Australia.
  • Fernando M; Smiling for Smiddy Research Group, Translational Research Institute, Mater Research Institute-The University of Queensland, Brisbane, Australia.
  • Daignault SM; Smiling for Smiddy Research Group, Translational Research Institute, Mater Research Institute-The University of Queensland, Brisbane, Australia.
  • Lanagan C; Translational Research Institute, The University of Queensland-Diamantina Institute, Brisbane, Australia.
  • Walpole S; Smiling for Smiddy Research Group, Translational Research Institute, Mater Research Institute-The University of Queensland, Brisbane, Australia.
  • Bonazzi V; Translational Research Institute, The University of Queensland-Diamantina Institute, Brisbane, Australia.
  • Skalamera D; Translational Research Institute, The University of Queensland-Diamantina Institute, Brisbane, Australia.
  • Snell C; Translational Research Institute, Queensland University of Technology, Brisbane, Australia.
  • Haass NK; Smiling for Smiddy Research Group, Translational Research Institute, Mater Research Institute-The University of Queensland, Brisbane, Australia.
  • Larsen JE; Smiling for Smiddy Research Group, Translational Research Institute, Mater Research Institute-The University of Queensland, Brisbane, Australia.
  • Gabrielli B; Mater Pathology, Mater Adults Hospital, Mater Misericordiae Limited, South Brisbane, Australia.
Mol Oncol ; 13(7): 1503-1518, 2019 07.
Article em En | MEDLINE | ID: mdl-31044505
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Desoxicitidina / Inibidores de Proteínas Quinases / Hidroxiureia / Neoplasias Pulmonares / Melanoma / Antimetabólitos Antineoplásicos Limite: Animals / Female / Humans Idioma: En Revista: Mol Oncol Assunto da revista: BIOLOGIA MOLECULAR / NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Desoxicitidina / Inibidores de Proteínas Quinases / Hidroxiureia / Neoplasias Pulmonares / Melanoma / Antimetabólitos Antineoplásicos Limite: Animals / Female / Humans Idioma: En Revista: Mol Oncol Assunto da revista: BIOLOGIA MOLECULAR / NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Austrália